Viral dynamics and Resistance Implications for HCV drug development

Similar documents
Clinical Applications of Resistance Stuart C. Ray, MD

Protease inhibitor based triple therapy in treatment experienced patients

The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany

Antiviral agents in HCV

Direct acting anti-virals: the near future

Oral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside

Bristol-Myers Squibb. HCV Full Development Portfolio Overview. Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013

How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy

Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors

Evolution of Therapy in HCV

Interferon-based and interferon-free new treatment options

New Therapeutic Strategies: Polymerase Inhibitors

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

Hepatitis C Resistance Associated Variants (RAVs)

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:

Hepatitis C Treatment 2014

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients

NS5A inhibitors: ideal candidates for combination?

Treatment of chronic hepatitis C in HIV co-infected patients

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

Treatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.

VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES

CURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA

ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT

SYNOPSIS Final Clinical Study Report for Study AI444031

Study Design - GT 1 Retreatment

Strategies towards cure of HCV infection: a personalized approach. Heiner Wedemeyer Hannover Medical School Hannover, Germany

Introduction to the Impact of Resistance in Hepatitis C

Treatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA

Resistencias & Epidemiología. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña

Meet the Professor: HIV/HCV Coinfection

David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado

Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona

Experience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona

Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?

Antiviral treatment in HCV cirrhotic patients on waiting list

Current Treatments for HCV

Hepatitis C Therapy Falk Symposium September 20, 2008

Significance of Hepatitis C. The Evolving Burden of Hepatitis C. The Bad News... The Good News... Chronic Hepatitis C Can be Cured

Treatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain

Predictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid

29th Viral Hepatitis Prevention Board Meeting

Update in the Management of Hepatitis C: What Does the Future Hold

New developments in HCV research and their implications for front-line practice

HCV Drug Resistance: Regulatory Perspective

The Liver Meeting 2013: The 64th Annual Meeting of the AASLD Washington, DC, November 1 5, 2013 Presentation LB-1

HCV Resistance Associated variants: impact on chronic hepatitis C treatment

10/21/2016. David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors

HCV Case Study. Treat Now or Wait for New Therapies

Hepatitis C Management and Treatment

Pharmacological management of viruses in obese patients

Clinical Management: Treatment of HCV Mono-infection

Management of HCV in Prior Treatment Failure

New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD

Treating HCV Genotype 2 & 3

Baseline and acquired viral resistance to DAAs: how to test and manage

HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London

Treatments of Genotype 2, 3,and 4: Now and in the future

ABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1

Didactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching

HCV MEDICATIONS & Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati

Future strategies with new DAAs

TREATMENT OF GENOTYPE 2

Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London

2.0 Synopsis. ABT-450/r, ABT-267 M Clinical Study Report R&D/17/0539. (For National Authority Use Only)

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

Genetic Determinants in HCV

What do we need to know about RAVs clinically?

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration

Best of AASLD 2010 For IAGH. April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS

Highlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases

Ledipasvir-Sofosbuvir (Harvoni)

Hepatitis C. Core slides

Express Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011

Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial

Hepatitis B New Therapies

MEDIC CENTER. Case 2

Should Elderly CHC Patients (>70 years old) be Treated?

Hepatitis C in Special Populations

Treatment of chronic hepatitis B 2013 update

Virological Tools and Monitoring in the DAA Era

ةي : لآا ةرقبلا ةروس

The Changing World of Hepatitis C

HCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London

Treatment of Unique Populations Raymond T. Chung, MD

Optimal Treatment with Boceprevir. Michael Manns

Treatment Targets HCV Genotype 1 & PIs Treating HCV G2&3 Future Therapies. Advances in treatment of HCV Dr John F Dillon

EASL and The Future of HCV Treatment

Saeed Hamid, MD Alex Thompson, MD, PhD

HIV, HBV, HCV Virology. Anna Maria Geretti Institute of Infection & Global Health University of Liverpool

What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago

Case #1. Case #1. Case #1: Audience vote VS. The Great Debate: When to Treat HCV in our HIV coinfected patients

2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956

Associate Professor of Medicine University of Chicago

SOLAR-1 (Cohorts A and B)

Handelsbanken November Bertil Samuelsson VP Discovery Research Rein Piir CFO / IR

Horizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688

Transcription:

Viral dynamics and Resistance Implications for HCV drug development Robert T. Schooley, M.D. University of California, San Diego June 23, 2011

SVR Rate Priorities in HCV Therapeutics 100 90 80 70 60 50 40 30 20 10 0 Treatment Modality

RNA copies/ml 10 7 10 6 10 5 10 4 10 3 10 2-10 -5 0 5 10 15 20 25 30 Days

4 x 10 8 3 x 10 10 virions/day

Two Compartment Model of HIV-1 Replication Productively infected CD4 lymphocytes 10 10 viral particles/day 2.6 days per generation >99% of replication T 1/2 ~6 hours <1% of replication Uninfected CD4 lymphocytes <1% Uninfected, activated CD4 lymphocytes Long-lived cell populations (macrophages) CD4 lymphocytes infected with defective virus

Conclusions From our study and previous reports, it is now clear that raging fire of viral replication (left side of slide, Fig 2) could be put out by potent antiretroviral agents in 2 3 weeks. However the dynamics of other viral compartments must also be understood.

Implications of HIV Dynamics and Replicative Fidelity for Mutational Barrier HIV= 4 x 10 8 3 x 10 10 virions/day Ribeiro et.al. AIDS, 1998.

RNA Change (Log 10 Copies/mL) Protocol 035 (Indinavir + ZDV + 3TC) Change in Viral RNA from Baseline 0 Double-Blind Only Double-Blind and Open Label Open Label Only 0-1 -1-2 -2-3 EFV+ZDV+3TC IDV ZDV+3TC 0 24 52 76 100 Weeks in Study N= N= N= Median Baseline HIV RNA = 4.64 Log 10 copies/ml (43,190 copies/ml) 30 30 31 29 28 33 29 29 32 27 25 29-3

Modeling of HCV Kinetics with Interferon Therapy HCV: 4 x 10 10 1 x 10 13 virions/day HIV= 4 x 10 8 3 x 10 10 virions/day 100 to 3000 fold more HCV produced/day than HIV Zeuzem, Clinics in Liver Disease, 2001

Viral RNA The HCV Polymerase has Two Shots at Goal Integrated DNA Viral RNA + Strand - Strand + Strand Reverse Transcriptase Transcription HIV Life Cycle RNA Polymerase RNA Polymerase HCV Life Cycle

Slide #11 Genetic Diversity of HIV and HCV HIV G 92NG083 A U455 E 93TH253 H 90CF056 C C2220 B RF F 93BR020 D NDK Distance 0.1 J8 2b ED43 4a VN004 9a VN405 8a VN235 7a JK046 11a BEBE1 2c J6 2a Th580 6b HCV A 1b HCV J 1b G9 1c HCV 1 1a H77 H90 Tr 3b NZL1 3a HK2 6a HCV H1480 5a JK049 10a Source: S Ray

Viral characteristics relating to Slide #12 resistance potential HCV 10 12 virions/day Error prone viral polymerase (x2) Viral quasi-species No overlapping reading frames Moderate infected cell turnover Eradication possible (no known latency) HIV 10 10 virions/day Error prone viral polymerase Viral quasi-species Overlapping reading frames Rapid infected cell turnover Eradication not possible? (Integrated pro-viral DNA)

Based Strictly on Viral Dynamics and Replicative Fidelity, HCV should Pose a Greater Challenge than HIV in Terms of Drug Resistance

Evolution of Drug Resistant HCV under Telaprevir Therapy

Log 10 Viral Load (IU/mL) Variant Frequency, % Individual Viral Load Plots from Patients infected with Genotype 1a Virus P/R + BOC Follow-up 7 6 5 Longitudinal Analysis Wk 28 Quantification of Variants 100 Week 28 Week 100 75 4 50 3 2 1 Total Viral Load V36M R155K 0 5 10 15 20 25 30 35 40 45 50 75 100 Week 25 0 Courtesy of Richard Bernhard, Ph.D.

Background OMe MeO 2 CHN N O N N H H N BMS-790052 (`052) N O N NHCO 2 Me Cl O O NH O N O N O H N O N H O O S BMS-650032 (`032) BMS-790052 is a first-in-class, highly selective HCV NS5A inhibitor with picomolar in vitro potency and broad genotypic coverage 1 BMS-650032 is a potent and selective HCV NS3 protease inhibitor 2 Combination of BMS-790052 and BMS-650032 yielded additive to synergistic activity in the replicon system No clinically important pharmacokinetic interaction 3 1 Gao M. Nature 2010;465:96-100. 2 McPhee F. J Hepatol 2010;52(Suppl1):S296. 3 Bifano M. Hepatology 2010;52(Suppl1):719A. 16

Study Design Study AI447-011 (Phase IIA, open label, randomized trial) Sentinel Cohort Group A BMS-790052 + BMS-650032 (n = 11) follow-up x 48 weeks Group B BMS-790052 + BMS-650032 + pegifnα/rbv (n = 10) follow-up x 48 weeks 24-week treatment Post-treatment Week 12: SVR 12 BMS-790052 (NS5A inhibitor) 60 mg PO QD BMS-650032 (NS3 protease inhibitor) 600 mg PO BID pegifnα-2a 180 µg SC once weekly RBV 1000-1200 mg daily according to body weight 17

Undetectable HCV RNA (Percent of patients) Virologic Response During and After Treatment 100 90 100 100 90 * * 80 60 40 64 60 60 7 6 36 6 46 46 5 9 5 10 10 Group A BMS-790052 + 9 BMS-650032 36 36 Group B BMS-790052 + BMS-650032 + pegifnα/rbv 20 4 4 4 n = 0 11 10 11 10 11 10 11 10 11 10 11 10 RVR ervr cevr EOTR SVR 12 SVR 24 Four (2/9 GT 1a and 2/2 GT 1b) patients in Group A achieved SVR 12 and SVR 24 10/10 subjects in Group B achieved SVR 12 and 9/10 subjects undetectable at SVR 24 *Group B: 1 patient at week 12 on therapy and another at week 24 post treatment with HCV RNA < LLOQ, both undetectable on retesting 35 days later 18

HCV RNA (log 10 IU/mL) HCV RNA by Patient: Group A BMS-790052 + BMS-650032 follow-up 7 6 5 4 3 2 1 0 1 2 3 4 6 8 10 12 16 20 Week 24 PT4 PT12 PT24 LLOQ LLOD Six patients (all genotype 1a) experienced viral breakthrough on therapy One patient with EOTR experienced viral relapse at 4 weeks post-treatment PT, post-treatment. 19

Why Might HCV More Responsive to Therapy than it Should Be Based on Viral Dynamics and Fidelity Modeling? 1. HCV is cleared ~30% of the time during acute infection During this phase, the virus is exquisitely sensitive to interferon 2. Acceleration of second phase kinetics with increasing regimen potency 3. Antiviral therapy and the equipoise between HCV and innate/adaptive immunity

Slide #21 HCV Is Cleared in Acute Infection in a Subset of Patients Acute Hepatitis C Resolved 15-30% Stable <80% Chronic Hepatitis 70-85% Cirrhosis 20%-50% 20 to 30 Years Stable 75% Decompensation 25% HCC 1%-4%/yr

Spontaneous Clearance of HCV in Symptomatic Patients Slide #22 Gerlach, Gastroenterology, 2003

Slide #23 IL28B Allele also Drives HCV Clearance in Acute Infection Thomas, Nature, 2009

Slide #24 Clearance of HCV During Acute Infection With Interferon Therapy Average time from infection ->therapy: 89 days Interferon alpha 5 mu qd x 4 weeks, then 5 mu three times weekly for 24 weeks Jaekel, NEJM, 2001

Why is HCV More Responsive to Therapy than it Should Be Based on Viral Dynamics and Fidelity Modeling? 1. HCV is cleared ~30% of the time during acute infection During this phase, the virus is exquisitely sensitive to interferon 2. Acceleration of second phase kinetics with increasing regimen potency 3. Antiviral therapy and the equipoise between HCV and innate/adaptive immunity

Decay Kinetics of HCV with Interferon-Based Therapy Rong and Perelson, Crit Rev Immunol 2010

Guedj and Perelson, Hepatology 2011

Open symbols: Telaprevir Closed Triangles: Telaprevir + Ifn Telaprevir Interferon 10 mu/day Interferon 10 mu/day + Ribavirin Guedj and Perelson, Hepatology 2011

Guedj and Perelson, Hepatology 2011

Potential Biological Explanations With increasing potency, infected cells are eliminated more quickly but no increase in hepatocellular enzymes With increasing potency, infected cells are being cleared of their HCV replication complexes With more effective suppression of viral replication, the ability of the virus to abrogate innate immunity that is stimulated by HCV through RLR and TLR pathways is compromised

Infection of Hepatocytes by HCV Activates Innate Immunity via the RIG-I Pathway RIG-I IPS-1 MAPK NF-κB IRF3 IRF7 Ifn-β Ifn-α

Liu and Gale, Gastroenterology Res and Practice, 2011

Infection of Hepatocytes by HCV Activates Innate Immunity via the RIG-I Pathway HCV NS3/4a RIG-I IPS-1 MAPK NF-κB IRF3 IRF7 Ifn-β Ifn-α

Liang, et. al. Gastroenterology, 2008

IL-8 Horner and Gale, J. Interferon and Cytokine Res, 2009

HCV and the Innate Immune Response HCV Innate Immune Response

HCV and the Innate Immune Response HCV Innate Immune Response Acute Infection -> Chronic Infection

HCV and the Innate Immune Response HCV Innate Immune Response Resetting the Balance with Potent and Sustained Antiviral Therapy

EASL, 2011

Fold Change Drug Susceptibility (log) Change in Drug Susceptibility Over Time Subject 16 Week 2 Subject 2 Week 7 Subject 5 Week 11 ZDV 3TC ABC NVP SQV RTV NFV Time (weeks)

Log 10 Viral Load (IU/mL) Log 10 Viral Load (IU/mL) Individual Viral Load Plots from Patients infected with Genotype 1b Virus 8 7 6 5 4 Genotype 1b Patient 1 T54A/S & V170A WT WT WT WT T54S T54S & V55A 8 7 6 5 4 WT T54A V158I/M Genotype 1b Patient 1 T54A WT 3 2 3 2 T54A 1 1 0-16 BL 16 32 48 64 80 96 112 128 144 160 172198 Time (Weeks) P/R Lead-In P/R + BOC 0-16 BL 16 32 48 64 80 96 112 128 144 160 172198 Time (Weeks) Courtesy of Richard Bernhard, Ph.D. Follow-up WT Wild Type at specific RAV loci BL Baseline

Linkage of Resistance Mutations WT HIV-1 WT HCV

Interim Conclusions Remarkable improvements have been seen with first generation HCV PI s when added to SOC Evidence may be emerging that with increasingly potent and sustained antiviral pressure the sum is greater than its parts. It is possible that this is attributable in part to abrogation of the innate immune evasion tactics of HCV

Many Questions Remain Is it especially beneficial (or even essential) to include an NS3/4a HCV protease inhibitor as a component of a potent regimen? How important is continuous and sustained antiviral pressure? Is it especially important to take resistance to resistance into account? Are we correct about the resistance linkage issue? What are the implications for retreatment after treatment failure?

Interim Recommendations We must continue with pilot sized test of principal studies as the traditional pathway to approval studies continue. We should take full advantage of all available molecular virological tools to quantify and characterize the HCV quasispecies in therapeutic interventions. As in the case of HIV-1, it is essential that we take advantage of therapeutic interventions to better understand fundamental virus-host interactions.

Integration of Clinical and Fundamental Biological Research is Essential Clinical and Translational Investigation Fundamental Biological Insights

HCV Therapy at a Crossroads: Where is Reality in the Optimism/Pessimism Spectrum?

Thank You Acknowledgements Richard Bernhard, MSD Steve Schnittman, BMS